Last reviewed · How we verify
GW640385
GW640385 is a HIV-1 integrase inhibitor.
GW640385 is a HIV-1 integrase inhibitor. Used for Treatment of HIV-1 infection.
At a glance
| Generic name | GW640385 |
|---|---|
| Sponsor | ViiV Healthcare |
| Drug class | HIV-1 integrase inhibitor |
| Target | HIV-1 integrase |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 2 |
Mechanism of action
GW640385 works by inhibiting the HIV-1 integrase enzyme, which is essential for the integration of viral DNA into the host genome, thereby preventing the replication of the virus.
Approved indications
- Treatment of HIV-1 infection
Common side effects
- Nausea
- Diarrhea
- Fatigue
Key clinical trials
- A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults (PHASE2)
- GW640385 Plus Ritonavir And NRTIs For 48 Weeks In HIV-1 Infected Adults (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GW640385 CI brief — competitive landscape report
- GW640385 updates RSS · CI watch RSS
- ViiV Healthcare portfolio CI